 Moodys Investors Service Moodys affirmed the Aaa long-term ratings of Johnson Johnson JJ, as well as the Prime-1 short-term rating. The rating affirmation follows the announcement that JJ will acquire Momenta Pharmaceuticals, Inc. Momenta for approximately 6.5 billion. Despite an increase in debtEBITDA to fund the Momenta acquisition, JJs Aaa rating reflects its excellent business profile and a financial profile that supports deleveraging, stated Michael Levesque, Moodys Senior Vice President. 